Bioblast Pharma (NASDAQ: ORPN) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
This is a summary of recent ratings for Bioblast Pharma and Microbot Medical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bioblast Pharma presently has a consensus price target of $3.15, suggesting a potential upside of 21.62%. Given Bioblast Pharma’s higher probable upside, analysts plainly believe Bioblast Pharma is more favorable than Microbot Medical.
Volatility and Risk
Bioblast Pharma has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500.
This table compares Bioblast Pharma and Microbot Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
1.5% of Bioblast Pharma shares are held by institutional investors. Comparatively, 4.7% of Microbot Medical shares are held by institutional investors. 31.8% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Bioblast Pharma and Microbot Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bioblast Pharma||N/A||N/A||-$16.02 million||($2.57)||-1.01|
|Microbot Medical||$120,000.00||340.97||-$9.66 million||($0.69)||-1.54|
Microbot Medical has higher revenue and earnings than Bioblast Pharma. Microbot Medical is trading at a lower price-to-earnings ratio than Bioblast Pharma, indicating that it is currently the more affordable of the two stocks.
About Bioblast Pharma
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich’s ataxia) and BBrm-02. The Company’s product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.
About Microbot Medical
Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.
Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.